Levoquin Injection (Levofloxacin Hydrate)

Adult administration

1. Generally administered by intravenous drip once or twice a day. Dosage should be determined based on the type and severity of the infection, as well as the suspected causative organism's susceptibility. 2. This medication should only be administered via intravenous infusion and can be used for a maximum of 14 days once or twice daily. The infusion time should take at least 60 minutes or more. 3. Dosing for patients with normal kidney function (creatinine clearance > 50 mL/

This drug is a fluoroquinolone antibiotic and can cause serious side effects such as tendon-related issues like tendinitis or tendon rupture, peripheral neuropathy, central nervous system disorders, and aggravation of myasthenia gravis. If such symptoms occur, use of this drug must be discontinued immediately, and it should not be used in patients with myasthenia gravis. This drug should only be administered when there are no other treatment alternatives for acute bacterial rhinosinusitis, chronic bronchitis, and acute exacerbations of chronic obstructive pulmonary disease, simple urinary tract infections, or acute otitis media. When administered as an injection, it should be infused slowly over a minimum of 30 to 60 minutes, and if blood pressure drops suddenly, the infusion must be stopped immediately. Caution should be exercised in elderly patients, those with reduced kidney function, and when combined with corticosteroids, as the risk of tendinitis and tendon rupture is increased, and treatment should be discontinued immediately if pain or inflammation occurs. This drug may affect the central nervous system, leading to convulsions, dizziness, drowsiness, anxiety, hallucinations, and suicidal thoughts; hence it must be used cautiously in patients with a history of seizures. Additionally, cardiac side effects like arrhythmias or hypotension, and QT interval prolongation may occur, necessitating caution in patients with heart disease. This drug should not be administered to pregnant or breastfeeding women, people under 18 years of age, patients with epilepsy, or those who have had hypersensitivity reactions to this drug. Diabetic patients on blood glucose control medications should monitor for changes in blood glucose levels, and treatment should be stopped immediately if allergic reactions such as rash or itching occur. Patients using this medication should avoid strong sunlight or artificial ultraviolet exposure, and care should be taken while driving or operating machinery as dizziness or drowsiness may occur. In cases of overdose, central nervous system symptoms and cardiac abnormalities may arise, requiring immediate medical attention, and this drug is not removed via hemodialysis. Finally, this drug may interact with certain medications, so patients taking other drugs should inform healthcare providers, and it should be stored in a light-protective container maintaining its original packaging.

Serious side effects

Hives, severe swelling (angioedema, swelling of the tongue, larynx, throat, and face), chest tightness, difficulty breathing, cold sweat, paleness, severe allergic reactions (anaphylactic shock, hypotensive shock), high fever with severe rash, blisters, skin peeling, mucosal pain in the mouth/eyes (Stevens-Johnson syndrome, toxic epidermal necrolysis, DRESS), serious neurological symptoms (seizures, altered consciousness, convulsions), difficulty breathing or breathlessness

Mild side effects

• Itching
• rash
• nausea
• diarrhea
• loss of appetite
• vomiting
• abdominal pain
• indigestion
• abdominal bloating
• constipation

This drug should be stored in a closed container that can block light, and it is recommended to keep it at room temperature between 1 to 30 degrees Celsius. Proper storage helps maintain the drug’s effectiveness over time.

Appearance

A clear yellowish solution with a light green hue in a colorless transparent vial injection.

Package unit

50 milliliters, 100 milliliters, 150 milliliters/vial × 1, 2, 5, 10